Splenomegaly, or enlargement of the spleen, is common in patients with Philadelphia-negative myeloproliferative neoplasms, and it is associated with symptoms like early satiety and abdominal pain. The ...

Ruxolitinib demonstrated a significant reduction in spleen volume (SV) and improvements in myelofibrosis (MF)-related symptoms in the COMFORT-I study, reported upon at the American Society of ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous outflow ...

Findings from a retrospective analysis support the use of splenectomy for patients with progressive disease and large splenomegaly. New study findings indicate massive splenomegaly could have a ...

Myelofibrosis (MF) is the most symptomatic of the myeloproliferative neoplasms and is characterized by debilitating constitutional symptoms, cytopenias, splenomegaly and bone marrow fibrosis. A ...

The National Institute for Health and Care Excellence (NICE) has recommended fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms of primary myelofibrosis, post-polycythemia vera ...

Please provide your email address to receive an email when new articles are posted on . The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with ...

Ojjaara helps patients with myelofibrosis by reducing spleen size, easing symptoms, and improving anemia to boost independence from blood transfusions. Ojjaara (momelotinib) is the first treatment of ...

About 20% of patients with myelofibrosis initially have no symptoms, allowing many cases to exist under the clinical suspicion of primary care clinicians. The need to treat asymptomatic or minimally ...